Skip to main content
OpenTrials

Clinical trial condition

Lymphatic Diseases

Explore clinical trials studying Lymphatic Diseases. Study availability and eligibility vary by location and protocol.

8,960 public trials 1,827 recruiting studies
Refine in advanced search Browse all conditions

Lymphatic Diseases trial results

Recruiting

A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease (NPC)

NCT07082725

Conditions
Brain Diseases, Brain Diseases, Metabolic, Brain Diseases, Metabolic, Inborn, +20 more
Locations
  • UCSF Children's Hospital and Research Center at Oakland Oakland, California, United States
  • University of Minnesota Medical School Minneapolis, Minnesota, United States
  • Mayo Clinic Children's Center - PIN Rochester, Minnesota, United States
  • Children's Medical Center Dallas Dallas, Texas, United States
View all 34 locations
View Trial Details
Recruiting

Efficacy and Safety Study of OATD-01 in Patients With Active Pulmonary Sarcoidosis

NCT06205121

Conditions
Hemic and Lymphatic Diseases, Hypersensitivity, Hypersensitivity, Delayed, +9 more
Locations
  • Molecure Investigative Site Birmingham, Alabama, United States
  • Molecure Investigative Site Kansas City, Kansas, United States
  • Molecure Investigative Site Baltimore, Maryland, United States
  • Molecure Investigative Site Rochester, Minnesota, United States
View all 28 locations
View Trial Details
Recruiting

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

NCT06317662

Conditions
Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia, Burkitt Lymphoma, +20 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • Providence Alaska Medical Center Anchorage, Alaska, United States
  • Banner Children's at Desert Mesa, Arizona, United States
  • Arkansas Children's Hospital Little Rock, Arkansas, United States
View all 113 locations
View Trial Details
Recruiting

A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease, GM1 Gangliosidosis or GM2 Gangliosidosis

NCT07054515

Conditions
Brain Diseases, Brain Diseases, Metabolic, Brain Diseases, Metabolic, Inborn, +25 more
Locations
  • UCSF Children's Hospital and Research Center at Oakland Oakland, California, United States
  • University of Minnesota Medical School Minneapolis, Minnesota, United States
  • Mayo Clinic Childrens Center - PIN Rochester, Minnesota, United States
  • Children's Medical Center Dallas Dallas, Texas, United States
View all 38 locations
View Trial Details
Recruiting

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

NCT05139017

Conditions
DLBCL, Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, +10 more
Locations
  • Palo Verde Hematology/ Oncology Center, Ltd. ( Site 0175) Glendale, Arizona, United States
  • Beverly Hills Cancer Center ( Site 0184) Beverly Hills, California, United States
  • Bass Medical Group ( Site 0166) Walnut Creek, California, United States
  • Innovative Clinical Research Institute ( Site 0122) Whittier, California, United States
View all 135 locations
View Trial Details
Recruiting

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

NCT06890884

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • Infirmary Cancer Care ( Site 0157) Mobile, Alabama, United States
  • Ironwood Cancer & Research Centers ( Site 0204) Chandler, Arizona, United States
  • Palo Verde Cancer Specialists ( Site 0105) Glendale, Arizona, United States
  • City of Hope - Phoenix ( Site 0202) Goodyear, Arizona, United States
View all 139 locations
View Trial Details
Recruiting

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

NCT06717347

Conditions
Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • USA Mitchell Cancer Institute ( Site 0173) Mobile, Alabama, United States
  • Banner MD Anderson Cancer Center ( Site 0165) Gilbert, Arizona, United States
  • Banner MD Anderson Cancer Center - University Medical Center Phoenix ( Site 0167) Phoenix, Arizona, United States
  • The University of Arizona Cancer Center - North Campus ( Site 0124) Tucson, Arizona, United States
View all 268 locations
View Trial Details

Related conditions